ATYR DEADLINE MONDAY: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages aTyr Pharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important December 8 Deadline in ...
aTyr Pharma, Inc. (ATYR)
Company Research
Source: GlobeNewswire
NEW YORK, Dec. 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16, 2025 and September 12, 2025, both dates inclusive (the “Class Period”), of the important December 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased aTyr Pharma common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the aTyr Pharma class action, go to https://rosenlegal.com/submit-form/?case_id=46109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage inve
Show less
Read more
Impact Snapshot
Event Time:
ATYR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATYR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATYR alerts
High impacting aTyr Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
ATYR
News
- aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary SarcoidosisGlobeNewswire
- Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Deliver On Growth Plans? [Yahoo! Finance]Yahoo! Finance
- Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) ShareholdersPR Newswire
- Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) ShareholdersGlobeNewswire
- ATYR Deadline: ATYR Investors with Losses Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud LawsuitPR Newswire
ATYR
Earnings
- 11/6/25 - Miss
ATYR
Sec Filings
- 1/9/26 - Form 4
- 1/9/26 - Form 4
- 1/9/26 - Form 4
- ATYR's page on the SEC website